Ocrevus (ocrelizumab) in Spain typically costs from $25,000 to $40,000 per year for private patients. Pricing depends on the specific clinic tier, city, and required pre-infusion diagnostic tests. In the US, similar treatments cost around $80,000 on average. Patients save around 59% compared to US list prices. Private costs in Spain usually include the medication, nursing care, and initial blood screenings.
Bookimed Expert Insight: Choosing a research-heavy center like Hospital Universitario HM Madrid or Centro Médico Teknon offers significant value. These clinics are led by experts like Dr. Rafael Arroyo González, who has led over 100 clinical trials. Patients benefit from JCI-accredited safety standards and extensive neurological expertise. Facilities in Barcelona and Madrid provide comparable pricing while maintaining some of the highest patient volumes in Europe.
Why do patients choose Spain for Ocrevus (ocrelizumab) treatment?
Access advanced Ocrevus (ocrelizumab) solutions in trusted clinics .
| Turkey | Austria | Spain | |
| Ocrevus (ocrelizumab) | from $10,000 | from $35,000 | from $25,000 |
Day 1: Arrival
Day 2: Pre-Operation
Day 3: Ocrevus (ocrelizumab) Infusion
Week 1-2: Post-Operation
Week 3-4: Rehabilitation
Please note that each patient"s experience with Ocrevus (ocrelizumab) can differ. Always consult with your healthcare team for personalized advice.
Principal investigator in 100+ clinical trials for neurological treatments, including Ocrevus studies. Dr. Arroyo leads Quironsalud Madrid's Neurology Department.
Dr Romero Imbroda leads the Neurology Unit at Quirónsalud Marbella, specializing in multiple sclerosis treatments like Ocrevus. His research includes cutting-edge therapies for MS.
A pioneer in movement disorders with _doctor_633_years_ of experience, Dr. Obeso leads the HM CINAC Integral Neurosciences Centre in Madrid.
Dr. Rodrigo Rocamora Zuniga is a neurologist who specializes in epilepsy. He leads the epilepsy department at HM Delfos Hospital in Spain. He is also a professor at UPF University. Dr. Rocamora earned his PhD from Bonn University in 2001. He completed his neurology training at Pontificia Universidad Católica de Chile and received his medical degree in Mendoza, Argentina.
Dr. Rocamora is accredited by the European Reference Network. He is an active member of SEN, CSUR, and EPI-Care. He has published over 100 scientific articles on drug-resistant epilepsy, epilepsy surgery, and cognitive impairment. His work has helped develop new protocols that have improved care for epilepsy patients.